Recent Securities Litigations

TG Therapeutics Inc. Common Stock (NASDAQ: TGTX)

38 Days left to seek lead plaintiff status.

Company Name:TG Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: TGTX
Class Period Start:01/15/2020
Class Period End (inclusive):05/31/2022
Filing Deadline:09/16/2022

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain FDA approval of the Umbralisib MZL/FL NDA, the U2 BLA, the U2 sNDA, or the Ublituximab RMS BLA in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.

TG Therapeutics Inc. Common Stock (NASDAQ: TGTX) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.